AKT1 and glioblastoma: A similar rationale has guided research interest in glioblastoma therapy towards PI3K/AKT/mTOR (phosphoinositide 3-kinase/ protein kinase B/ mammalian target of rapamycin) pathway inhibitors, which should impend cell survival and growth and regulate protein synthesis and cell metabolism.